Pharmacogenomics of Anti-Inflammatory Drugs explores genetic variations affecting the efficacy and safety of anti-inflammatory medications. It covers key genetic markers that predict responses to NSAIDs, corticosteroids, and biologic agents. The book emphasizes personalized treatment strategies to optimize inflammation control and reduce adverse effects. Suitable for rheumatologists and pharmacogenomic researchers, it advances tailored anti-inflammatory therapies.
William Henry investigates the pharmacogenomics of anti-inflammatory drugs used in dermatology to personalize treatments for inflammatory skin conditions like psoriasis and eczema. His research focuses on how genetic variations influence the efficacy and safety of corticosteroids and non-steroidal anti-inflammatory agents. William has published extensively on developing personalized anti-inflammatory therapy plans based on pharmacogenomic data to enhance treatment outcomes. He also provides guidelines for clinicians to incorporate pharmacogenomic strategies in managing inflammatory skin conditions, promoting personalized and effective dermatological care through tailored anti-inflammatory treatments.